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ABSTRACT Thestructuralandfunctionalsigniﬁcanceofsomaticinsertionsanddeletionsinantibodychainsisunclear.Here,we
demonstratethatanaturallyoccurringthree-amino-acidinsertionwithintheinﬂuenzavirus-speciﬁchumanmonoclonalanti-
body2D1heavy-chainvariableregionreconﬁgurestheantibody-combiningsiteandcontributestoitshighpotencyagainstthe
1918and2009pandemicH1N1inﬂuenzaviruses.Theinsertionarosethroughaseriesofevents,includingasomaticpointmuta-
tioninapredictedhot-spotmotif,introductionofanewhot-spotmotif,amolecularduplicationduetopolymeraseslippage,a
deletionduetomisalignment,andadditionalsomaticpointmutations.Atomicresolutionstructuresofthewild-typeantibody
andavariantinwhichtheinsertionwasremovedrevealedthatthethree-amino-acidinsertionnearthebaseofheavy-chain
complementarity-determiningregion(CDR)H2resultedinabulgeinthatloop.ThisenlargedCDRH2loopimpingesonadja-
centregions,causingdistortionoftheCDRH1architectureanditsdisplacementawayfromtheantigen-combiningsite.Re-
moval of the insertion restores the canonical structure of CDR H1 and CDR H2, but binding, neutralization activity, and in vivo
activitywerereducedmarkedlybecauseofstericconﬂictofCDRH1withthehemagglutininantigen.
IMPORTANCE AntibodydiversiﬁcationthroughVDJgenerecombination,junctionalvariation,andsomatichypermutationhas
clearimportanceforthegenerationofmature,high-afﬁnityantibodies.Between1.3and6.5%ofantibodyvariablegenese-
quenceshavebeenreportedtocontaininsertionsordeletions,buttheirstructuralandfunctionalsigniﬁcanceremainslesswell
deﬁned.Thepandemicinﬂuenzavirushemagglutininantibody2D1datasuggestthatsomaticinsertionsanddeletionsinanti-
bodygenescontributeimportantstructuralandfunctionalfeatures.Wepredictthatsuchfeaturescanbecriticalforafﬁnityand
functionalmaturationofthehumanantibodyrepertoire.
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T
he breadth of antibody repertoires is shaped by combinatorial
and junctional diversity during B cell ontogeny and the intro-
duction of somatic point mutations during germinal center reac-
tions. It has also been noted that some heavy- and light-chain
genes contain somatically introduced insertions or deletions (1–
5), but the functional and structural signiﬁcance of such alter-
ations in human antibodies remains unclear due to the low num-
ber of human antibodies studied to date and a paucity of
crystallographic data from antibodies with such insertions or de-
letions.
2D1 is an IgG1/ human monoclonal antibody (MAb) de-
rived from a circulating B cell in the peripheral blood of a 1918
inﬂuenza pandemic survivor (6). MAb 2D1 was originally iso-
lated as a 1918-speciﬁc antibody, which was made possible by
reconstruction of the virus from RNA sequences recovered
from the preserved tissues of victims (7). In April 2009, a novel
inﬂuenzaAH1N1virus(2009H1N1)causedanoutbreakstart-
ing in Mexico that spread globally and developed into the ﬁrst
human inﬂuenza pandemic in 40 years (8). Early sequence and
serological analyses suggested that the 1918 and 2009 H1N1
hemagglutinins (HAs) were antigenically similar, as parts of
the four main antigenic sites (Ca, Cb, Sa, and Sb) were well
conserved (9–12). Indeed, MAb 2D1 binds and neutralizes
both the 1918 and 2009 H1N1 pandemic inﬂuenza viruses be-
cause the 2D1 epitope in the Sa site of the 1918 virus HA pro-
tein was conserved in swine inﬂuenza viruses for almost a cen-
tury prior to its reintroduction by reassortment into a virus
that caused the pandemic 2009 human outbreak (12, 13).
Previous sequence analysis revealed that MAb 2D1 was pre-
dicted to derive from the human VH2-70 gene segment (6). In
additiontoconventionalpointmutations,theantibodyalsohasa
9-bp insertion in framework 3 (FR3) of the heavy chain adjacent
to CDR H2 (Fig. 1). The atomic resolution structure of MAb 2D1
in complex with 1918 inﬂuenza virus HA determined by X-ray
crystallography revealed an unusual conformation and relative
disposition of the CDR H1 and CDR H2 loops in this potent
neutralizing MAb (12).
Here we describe work in which the 9-bp insertion that is
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MAb del 2D1, thus reverting the antibody structure to a more
conventional conﬁguration characteristic of antibodies encoded
by the predicted 2D1 germ line gene sequence VH2-70. We found
that removal of the insertion restored the canonical conforma-
tionsofheavy-chainCDRsH1andH2.Furthermore,comparison
of the antibodies showed that acquisition of the somatic insertion
during development of the mature antibody led to enhanced af-
ﬁnityofbinding,hemagglutinationinhibition(HAI)activity,and
in vivo therapeutic activity.
RESULTS
Genetic mechanism of insertion. Retrospectively, the genetic
mechanism resulting in the MAb 2D1 insertion cannot be deter-
minedwithcertainty;however,themostlikelyscenarioinvolveda
four-step process, as illustrated in Fig. 2. First, an initial somatic
point mutation resulted in a change from a TAAA sequence to a
TACA sequence in an antibody gene in the VH2-70 gene segment
(Fig. 2A). This ACA sequence and another ACA sequence just
12bpdownstream(bothshowninboldin
Fig. 2B) likely formed the basis of a gene
duplication: the second ACA triplet likely
annealed with the complementary TGT
triplet that would be expected to anneal
with the ﬁrst ACA triplet, leading to a
12-bp insertion. Subsequently, a similar
misalignment during replication of the
antisense strand likely resulted in a 3-bp
deletion,leadingtoanetinsertionof9bp
(Fig. 2C). Finally, an additional two so-
matic point mutations occurred, result-
ingintheﬁnalsequencethatwasfoundin
the mature wt 2D1 antibody gene
(Fig. 2A). The genetic insertion codes for
the addition of three amino acids (ITY)
near the base of CDR H2 (Fig. 1).
Role of hot-spot motifs. It is of inter-
est that the ﬁrst mutation, the TAAA-to-
TACA sequence change, occurred at a
previously deﬁned somatic hypermuta-
tion hot-spot motif (the consensus
sequenceWA,whereWisadenineorthy-
mine and A is adenine [14]). Interest-
ingly,theresultingmutationintroduceda
new hot-spot motif that occurred at the
site leading to the duplication event. The
TACA sequence is characteristic of the
WRCH consensus motif that is a strong
predictorofmutabilityinimmunoglobu-
linhypermutation(whereWisadenineor
thymine, R is the purine adenine or gua-
nine, C is cytosine, and H is thymine, cy-
tosine, or adenine [15]).
Effect of insertion on binding afﬁn-
ity. We tested whether the acquisition of
the insertion affected binding afﬁnity by
comparingthebindingoftheoriginalan-
tibody with that of a mutated form of the
antibody lacking the insertion. wt 2D1
Fab bound soluble 1918 HA with a KD of
8.4  109 M. In contrast, the steady-state afﬁnity of del 2D1 Fab
wasonly3.0107M,amarkedreductionof~35-fold.Interest-
ingly, the effect of the insertion on afﬁnity was mediated almost
entirelybytheeffectonthedissociationrate.Whiletheassociation
rateswerenearlyidentical(7.0104/Msfordel2D1versus8.1
104/M s for wt 2D1), del 2D1 Fab dissociated ~30 times more
readilyfromHA(2.1102/sfordel2D1versus6.8104/sfor
wt 2D1). It should be noted that this difference in binding was
mediated only by the insertion, as we did not alter any of the
predictedsomaticpointmutationsorjunctionalinsertionsfound
in the wt 2D1 MAb.
Effect of insertion on functional activity. We next tested
whetherremovaloftheinsertionaffectedthefunctionalactivityof
the antibody. wt and del 2D1 MAbs were tested for inhibitory
activityinanHAIassayagainstthe1918pandemicvirus[A/South
Carolina/1/1918 (H1N1)], a strain of the 2009 pandemic virus
[A/Mexico/4108/09 (H1N1)], and a seasonal inﬂuenza virus
strain [A/Brisbane/59/07 (H1N1)] (Table 1). The 1918 and 2009
pandemic viruses share essential elements of the Sa antigenic site
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FIG 1 Amino acids of the wt 2D1 antibody heavy-chain variable sequences in a standard Collier de
Perlestwo-dimensionalgraphicrepresentation(28).CDRH1isinred,CDRH2isinorange,andCDR
H3 is in slate blue. Hydrophobic amino acids and tryptophan (W), found at a given position in more
than 50% of the Ig sequences analyzed, are shaded in blue. All prolines are shaded in yellow. The CDR
boundaries are indicated by amino acids shown in squares. Hatched circles or squares correspond to
missing positions according to the IMGT unique numbering. Arrows indicate the direction of the beta
sheets and their strand designations in the three-dimensional structure. The insertion in the ﬂanking
regionofwt2D1CDRH2isindicatedbyagreenbox;thewt2D1antibodycontainsanITYinsertionof
threeaminoacidsinthebetastrandatthebaseofCDRH2.Thisinsertionwasremovedtogeneratethe
del 2D1 antibody, reﬂecting a reversion at that location to the predicted germ line sequence. Of note,
while this illustration conforms to IMGT nomenclature and CDR deﬁnitions, the numbering is based
on the Kabat numbering system to correspond to the standard positions in the crystal structures.
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sessespointmutationsinthatsitethatlikelywoulddisruptrecog-
nition by MAb 2D1, especially the introduction of two glycosyla-
tion sites. The wt 2D1 and del 2D1 antibodies both showed
signiﬁcant functional activity against the
1918 and 2009 pandemic viruses but did
not mediate HAI activity with the sea-
sonal H1N1 inﬂuenza virus, as expected.
The del 2D1 antibody mediated a 4-fold
lower level of HAI activity than wt 2D1
against the 1918 and 2009 pandemic vi-
ruses. Mouse or ferret immune sera used
as control reagents revealed the expected
patternsofactivity,basedonpreviousex-
periments (16–19).
Effect of insertion on in vivo antivi-
ral effect. We tested whether the differ-
ences in binding afﬁnity and functional
activity that we noted in these in vitro as-
says also would be seen when comparing
the two antibodies in vivo during a lethal
infection with inﬂuenza virus. In the an-
imal model, del 2D1 antibody was less ef-
fectivethanwt2D1inreducingvirusrep-
licationinthelung(Table2).Thewt2D1
antibody, given at a dose of 200 g per
mouse(~10mg/kg)at24hafterinocula-
tion, reduced the lung inﬂuenza virus ti-
ter over 25,000-fold compared to the hu-
man IgG control antibody preparation.
Incontrast,thedel2D1antibody,givenat
the same dose, was approximately 100-
fold less active in vivo, mediating only a
251-fold reduction in titer. del 2D1 was
less effective than wt 2D1 at every dose
tested.
Effect of insertion on in vivo thera-
peuticefﬁcacy.Thelevelofvirusreplica-
tion in vivo often correlates with disease
severity due to inﬂuenza virus infection.
Therefore, we tested whether the loss of
antiviral potency in vivo for del 2D1 also
was associated with a reduction of the
therapeutic effect against weight loss and
lethal infection. The results showed that
del2D1waslessprotectiveagainstweight
loss and death (Table 2; Fig. 3). At the
highest dose level of the MAbs tested
(200 g), wt 2D1 or del 2D1 protected all
six animals from a challenge with the virulent 1918 inﬂuenza A
virus, while none of the animals in the control group treated
withhumanIgGsurvived.Incontrast,attheintermediatedose
treatment level (20 g), we noted a marked difference in the
FIG 2 Predicted genetic mechanism of the naturally occurring 2D1 somatic insertion/deletion. (A)
Nucleotide sequences surrounding the insertion/deletion site of MAb 2D1 and its predicted germ line
VH gene segment sequence, VH2-70. The adjacent nucleotide sequence to which the insertion/deletion
is related is in bold. Shaded boxes highlight the repeat nucleotide sequence present prior to insertion/
deletion. The nucleotides in the inserted sequence that likely were mutated before (in italics) or after
(underlined) the insertion/deletion are indicated. (B) For the insertion to occur, the misaligned repeat
sequence (in bold) created a loop and a misaligned “foot” that was extended subsequently. The nucle-
otides that form the basis of the deletion in panel C are in red in panel B, part 5. (C) Similarly, a
misalignment in the antisense strand can lead to a deletion (according to de Wildt et al. [1]).
TABLE 1 HAI assay results of recombinant wt or del 2D1 MAb against representative inﬂuenza A H1N1 viruses compared with those of polyclonal
immune serum controls
H1N1 virus tested
Sp act of MAb (g/ml)a Mean reciprocal titer of immune serum to indicated inﬂuenza A virus (species)
wt 2D1 del 2D1 Mexico/4108/2009 (mouse) South Carolina/1/1918 (ferret) Brisbane/59/2007 (ferret)
A/South Carolina/1/1918 0.04 0.16 12 1,280 10
A/Mexico/4108/09 0.16 0.62 1,280 400 10
A/Brisbane/59/07 b   640
a Speciﬁc HAI activity of MAbs was calculated as the lowest concentration of MAb that displayed HAI activity. Shown are the mean results of four replicate experiments.
b , activity was not detected at any concentration tested, up to 5 g/ml.
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imals in the del 2D1 group succumbed to infection, while all of
the animals in the wt 2D1-treated group survived.
Structural basis for enhanced afﬁnity and function. We next
sought to understand the structural basis for acquisition of the
enhanced potency of wt 2D1 caused by the somatic insertion. We
previously determined the atomic resolution structure of wt 2D1
Fab in complex with 1918 virus HA protein (12). Here, we ob-
tainedcrystalsanddeterminedthestructuresofwt2D1Fabat1.55
Åresolutionanddel2D1Fabat1.65Åresolution(Fig.4and5;see
Table S1 in the supplemental material). We compared the struc-
tureofwt2D1ineitheritsboundorunboundconformationwith
that of a number of Fabs with similar CDR H1 amino acid se-
quences. While the overall structure of wt 2D1 resembles that of
other Fabs from the Protein Data Bank (PDB), both 1918 HA-
bound and free wt 2D1 Fabs differ markedly from sequence-
related Fabs in the vicinity of CDR H1. When bound to 1918 HA,
CDR H1 adopts an extended, open loop conformation (12) and
appearstobequiteﬂexibleoradoptmultipleconformations.Sim-
ilarly, in the structure of unbound wt 2D1, CDR H1 adopts an
extendedloopconformationinoneofthetwocopiesintheasym-
metricunit.Inthesecondcopy,CDRH1isdisordered,indicating
conformational plasticity in this loop. In contrast, CDR H1 as-
sumesarigid,uniformconformationinallofthesequence-related
Fabstructuresexamined,withthemiddleofthelooppackingback
againstthecoreofVH,resultinginacompact,coiledconﬁguration
(Fig. 4B).
Interestingly, the three-amino-acid insertion in wt 2D1 lies in
themiddleofthe-strandimmediatelyfollowingCDRH2,which
is part of the core of the immunoglobulin fold. Unlike insertions
intheturns,whichcaneasilybeaccommodatedbyextendingloop
length, insertion in the middle of a strand is more drastic, requir-
ingeitherabulgeoutwardfromthefaceofthe-sheetorashiftin
the register of the strand that displaces the inserted residues to-
ward the loop at either end. In wt 2D1, the insertion at the CDR
H2-FR3 junction triggers a shift in the register of the strand in
both directions from the point of insertion, with one amino acid
shifted N terminally, toward the tip of CDR H2, while the other
two inserted residues displace the rest of the strand C terminally
toward the turn at the opposite end, adjacent to the Fab constant
domains. The introduction of a single amino acid bulge in the tip
ofCDRH2resultsinaclashbetweenCDRsH1andH2,leadingto
a distortion of H1 and a modular shift of the loop away from
interaction with the HA surface. Thus, removal of the insertion
would be expected to restore the proper register of the -strand
and relieve the bulge from the tip of CDR H2, thereby allowing
CDR H1 to relax back into the more compact conformation ob-
servedinotherFabstructures.Thishypothesisisconﬁrmedbythe
structure of del 2D1 Fab, which lacks the three-amino-acid inser-
tion. As expected, the canonical conﬁgurations of CDRs H1 and
TABLE 2 Therapeutic efﬁcacy of wt and del 2D1 MAbs against virus replication and death in mice infected with 1918 inﬂuenza A virus
MAb and dose (g/mouse)
No. of survivors
among 6 animalsa
Mean lung virus titer
(log10 PFU/ml)  SDb
Lung virus titer reduction vs IgG control
(log10 PFU/ml)
wt 2D1
200 6 2.7  0.6 4.4
20 6 4.6  0.7 2.4
2 1 5.7  0.8 1.3
del 2D1
200 6 4.7  1.0 2.4
20 2 6.1  0.5 0.9
2 0 6.8  0.3 0.2
Human IgG control
200 0 7.1  0.7
20 0 7.0  0.2
2 0 7.0  0.5
a At the mid-dose level and the low-dose level, the differences in survival distribution between the wt 2D1 and del 2D1 groups were signiﬁcant by log-rank test (P  0.0178 for the
mid-dose level, P  0.0129 for the low-dose level).
b At the   0.0167 level controlling the overall type I error at 5%, the lung homogenates of the wt 2D1 group had a lower virus titer than those of the del 2D1 group at the 200-g/
ml level (P  0.01429) and at the 20-g/ml level (P  0.01429) by the Wilcoxon signed-rank test.
FIG 3 Therapeutic efﬁcacy of 1918 HA-speciﬁc MAbs against disease caused
bythe1918A(H1N1)virusinmice.Micewereinoculatedonday0andtreated
on day 1 with the indicated antibody and dose. In each group, six mice were
monitored every other day for weight (A) and survival (B).
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of sequence-related Fabs (Fig. 4B).
Comparison of the structure of del 2D1 with that of the wt
2D1/1918 HA complex explains how the three-amino-acid inser-
tion in wt 2D1 at the junction of CDR H2 and FR3 caused en-
hancement of antibody binding and function. Without the inser-
tion, interaction of del 2D1 Fab with the HA protein is
compromised by a steric clash between the common, compact
conﬁguration of CDR H1 and the target epitope on the HA anti-
gen (Fig. 5). The insertion in wt 2D1 mediates a bulge in the CDR
H2 loop that, in turn, impinges upon the base of CDR H1, result-
ing in the displacement of CDR H1 away from the HA surface,
thus resolving steric clashes with the HA.
DISCUSSION
We show here that a novel insertion coupled with somatic point
mutations in a human antibody framework region mediated a
major enhancement of binding and antiviral activity by second-
shell effects modulating the conformation and spatial disposition
of the heavy-chain CDR loops. The case of MAb 2D1 highlights
several interesting principles that may be
important in antibody afﬁnity matura-
tion and the generation of neutralizing
antibodies. First, the effect of the inser-
tion was indirect. Rather than altering
CDR H1 directly to relieve a steric clash,
an insertion near the CDR H2 loop was
selected that affected binding principally
by altering the orientation and relative
dispositionoftheadjacentCDRH1loop.
Second, the effect of the insertion was
surprising in that the mechanism was
subtractive. The CDR H1 displacement
resolved a steric conﬂict in the parental
antibody-antigen interaction by moving
a CDR away from the region of interac-
tion, rather than mediating a new inter-
action in the antibody-antigen interface.
Whileperhapsunderappreciated,remov-
ing conﬂicting and unfavorable interac-
tions may be nearly as important during
afﬁnity maturation as adding favorable
ones.
Insertions and deletions in antibody
gene sequences have been noted previ-
ously in reports on a subset of sequences
inantibodygenesfrommemoryBcellsin
lymphoid tissues, such as lymph node,
spleen, or synovial tissue (1–3, 5). The
percentage of memory cells with gene se-
quences containing insertions or dele-
tions was low (1.3 to 6.5% in previous
reports [1, 3, 5, 20]), although the true
frequency is not well deﬁned because of
the small numbers of cells that have been
testedtodate.Thesenovelalterationsap-
pear to result from DNA duplication
eventsfollowingDNAstrandbreaksdur-
ing the somatic hypermutation process.
Many of the insertions noted previously
occurred at mutational hot spots for error-prone DNA poly-
merases.Previousreportshaveestablishedthatinsertionsandde-
letions contribute to the genetic diversity of the antibody reper-
toireattheDNAlevel,butitislessclearifsuchalterationsmediate
structural or functional changes that enhance binding to the cor-
responding epitope. The data in this paper show that complex
structural rearrangements mediated by an insertion/deletion
eventcanmarkedlyenhancethebindingandfunctionofahuman
antibody against a major human pathogen.
Somatic hypermutation requires both hot spot-directed and
randomly directed processes (21). Somatic mutation hot spots
correspondtotheerrorspectrumofDNApolymerase(14).The
motif DGYW (D  A/G/T), its reverse complement WRCH (14,
15,20),andtheWAmotif(14)arepredictorsofhighmutabilityin
immunoglobulin hypermutation. The insertion that is observed
in wt 2D1 appears to be a result of a point mutation at a conven-
tionalWAmotif,followedbyaninsertionthatoccurredatthesite
of the motif WRCH that was introduced by the prior point muta-
tion. The activation-induced (cytidine) deaminase (AID) enzyme
is important for both class switch recombination and somatic
FIG 4 Insertion in 2D1 remodels the combining site loop architecture. (A) Superposition of VH
gene-derived regions from HA-bound wt 2D1 (PDB code 3LZF), free wt 2D1 Fab (PDB code 3QHZ),
and free del 2D1 (PDB code 3QHF). CDR H1 is highlighted in blue (2D1-HA complex), red (unbound
wt 2D1 Fab), and cyan (unbound del 2D1 Fab), with H2 in lighter shades. The ITY insertion (green
spheresinthewt2D1structures)triggersaregistershiftinthestrandandanextensionofCDRH2.This
extendedloopimpingesuponCDRH1,forcingitoutofitsusualpositionintothemoreopen,extended
conformationsobservedinwt2D1.(B)SamedepictionasinpanelAbutalsoshowingthesuperposition
oftheﬁvemostcloselyrelatedFabstructuresfromthePDB(onthebasisofVHsequencesimilarity[PDB
codes 2HWZ, 2AGJ, 3IFL, 1U92, and 2ROZ]). del 2D1 lies near the center of the cluster of related
structuresandisnoteasilyvisible.Thus,simplyrevertingtheITYinsertiontothegermlinesequenceis
sufﬁcient to restore the expected CDR H1 and H2 conformations.
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avidly on double-stranded DNA substrates containing a small
“transcription-like” single-stranded DNA bubble (31). The re-
sultant mismatch can lead to widespread DNA double-strand
breaks during times of high levels of transcription of antibody
genes (32) which can be repaired by nonhomologous end joining
(33), which would be an alternate explanation for the ins/del
events described here.
We showed previously that MAb 2D1 binds to and neutralizes
the 1918 and 2009 pandemic H1N1 viruses (13). Here, we also
show that MAb 2D1 did not show HAI activity against recent
seasonal H1N1 viruses, as would be expected based on the pres-
ence of glycosylation sites within the Sa site of such viruses (12).
del 2D1 bound 1918 HA about 35-fold less well than wt 2D1.
Likewise, the HAI activity of del 2D1 against the 1918 or 2009
pandemic virus was reduced 4-fold compared to that of wt 2D1.
del 2D1 also was less active in an in vivo model of therapeutic
efﬁcacy.Theseﬁndingssuggestedthattheinsertionwithinwt2D1
was critical for the acquisition of high potency of the antibody.
Interestingly, the insertion in wt 2D1 is within a -sheet. This is
surprising,asrandominsertionsordeletionsin-sheetsoftenwould
result in the disruption of this secondary structure and perhaps de-
stabilize the protein or interfere with folding. Here, a three-amino-
acid insertion was accommodated by a register shift in the -sheet
andbyachangeintheconformationoftheadjacentloop.Thecrystal
structures presented here suggest that this insertion in wt 2D1 does
not, in fact, lead to a “bulge” in the buried -sheet at the site of
insertionbutresultsinthedisplacementofthreeresiduesencodedin
the germ line sequence to cause a bulge in the external loop of CDR
H2. Subsequently, this alteration resulted in the displacement of
heavy-chain CDR H1 in the wt structure, a
featurenotpresentindel2D1.Heavy-chain
CDR H1 of wt 2D1 does not participate in
the interaction with the HA antigen (12).
However, heavy-chain CDR H2 is located
directly at the interface, and it seems that
the insertion near CDR H2 improves the
interaction, mainly by removing CDR H1
from the interacting region.
In conclusion, these studies show that
a somatic insertion/deletion can dramat-
ically impact both the structure and the
function of the resulting antibody. This
molecular mechanism may constitute a
major component of the diversiﬁcation
and enhancement of high-potency anti-
bodiesinthehumanantibodyrepertoire.
MATERIALS AND METHODS
Expression and puriﬁcation of wt 2D1 and
del 2D1. To prepare del 2D1 Fab or IgG1, we
used recombinant expression in mammalian
cells as previously described (12). Brieﬂy, the
MAb 2D1 heavy- and light-chain genes were
cloned into the pEE6.4 and pEE12.4 vectors,
respectively (Lonza). For production of Fabs,
a stop codon was introduced into the
heavy-chaingeneimmediatelyafterthecodon
for the cysteine of the hinge disulﬁde. The
QuikChange Primer design tool (Agilent) was
used to design site-directed mutagenesis
primers(Invitrogen)tocreateacDNAencod-
ing del 2D1 using the QuikChange II XL kit. The plasmid bearing the del
2D1heavy-chaingenewastransformedintoXL10-goldcellsforEndoFree
Plasmid Maxi DNA preparation (Qiagen) after sequence veriﬁcation
(Vanderbilt DNA Sequencing Facility). A plasmid encoding the wt 2D1
light chain was used for both MAbs. Heavy- and light-chain DNAs were
cotransfectedtransientlyintoHEK293Fcells(Invitrogen)usingPolyFect
reagent(Qiagen),andthecellswereincubatedinhumidiﬁedairwithCO2
in shaker ﬂasks. The supernatant was harvested, puriﬁed, and concen-
trated as previously described (12).
Biosensor studies. The binding afﬁnity of recombinant wt 2D1 and
del 2D1 Fabs for recombinant, trimerized, His-tagged HA protein con-
taining the sequence from the inﬂuenza virus A/South Carolina/1/1918
strain was measured using anti-Penta-HIS tips on the Octet QK platform
(FortéBio, Menlo Park, CA). Soluble HA protein was expressed and pu-
riﬁed as previously described (13).
HAI assays. HAI tests using full-length recombinant puriﬁed MAbs
were performed according to standard protocols (22). Brieﬂy, serial dilu-
tionsofpuriﬁedMAbsinphosphate-bufferedsaline(PBS)wereprepared
fromaninitialconcentrationof5g/ml.Serawereinitiallydiluted1:10in
receptor-destroying enzyme from Vibrio cholerae (Denka Seiken). Serial
dilutions of mouse positive-control sera or human MAbs were preincu-
bated with four HA units of virus per well. Turkey red blood cells (RBCs)
were added to a ﬁnal concentration of 0.5%, and the plate was incubated
at room temperature for 30 to 60 min. Serum titers were expressed as the
reciprocal of the highest dilution of serum inhibiting the agglutination of
0.5%oftheRBCsat4HAunitsofvirus.Normalmouseserumgaveavalue
of less than 10. The speciﬁc HAI activity of a MAb was calculated as the
lowest concentration of the MAb that displayed HAI activity.
Animalstudies.Female8-week-oldBALB/cmicewereinoculatedin-
tranasallywith1,00050%mouseinfectiousdosesina50-lvolumeofthe
virulentreconstituted1918virusaspreviouslydescribed(6).At24hafter
inoculation,micewereeachadministered200,20,or2g(approximately
FIG5 CombiningsitereconﬁgurationduetoITYinsertionrelievespotentialstericclashesbetweenthe
epitopeonHA(bottomleftingreyandcyan)andantibodyCDRs(topright).Superpositionofdel2D1
Fab onto the wt 2D1-HA complex structure, with Fabs oriented approximately as in Fig. 4. In the germ
line conﬁguration, the base of CDR H1 and the Trp52a side chain from CDR H2 would be in conﬂict
withanHAepitopeloop.TheITYinsertionandextendedCDRH2inwt2D1pushTrp52aupandaway
from the epitope, simultaneously displacing CDR H1 from its usual position, allowing wt 2D1 to
recognize HA in a manner that is otherwise unfavorable for the germ line Fab.
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human IgG (Sigma) by the intraperitoneal route in groups of 10 mice.
Micewereobservedforweightlosseveryotherdayfor14days.Subsetsof
four animals treated with MAbs were euthanized on day 3 after infection,
and whole lungs were homogenized in 1 ml of sterile PBS. Virus titers in
lung tissue homogenates were determined by plaque titration in MDCK
cell monolayer cultures. The limit of virus detection was 100.95. Statistical
analyseswereperformedwithR(theRProjectforStatisticalComputing).
Survival distributions between antibody-treated groups were compared
using the nonparametric log-rank test. The Wilcoxon signed-rank test
wasusedtocomparevirustiters,whichcannotbeassumedtobenormally
distributed.
Crystallizationandstructuredeterminationofwt2D1anddel2D1.
wt 2D1 Fab was generated by proteolysis of intact IgG with endoprotein-
ase Lys-C. Recombinant del 2D1 Fab was expressed as described above,
with a stop codon in the heavy-chain constant domain after the cysteine
codon in the hinge disulﬁde region. Fab proteins were puriﬁed by afﬁnity
chromatography using CaptureSelect lambda resin (BAC B.V.). The
eluted material was buffer transferred to 50 mM sodium acetate buffer,
pH 5.0, and subjected to cation-exchange chromatography using a
MonoS resin (GE Healthcare). After a ﬁnal gel ﬁltration step to remove
any aggregates, the Fabs were concentrated to approximately 15 mg/ml
and screened for crystallization conditions using the robotic Crystalma-
tionplatformattheJointCenterforStructuralGenomics(JCSG).Crystals
for each Fab were obtained under several conditions. Crystals for diffrac-
tiondatacollectionweregrownat20°Cinsittingdropsbyvapordiffusion
with a reservoir containing 22% PEG 4000 and 150 mM calcium acetate
(wt 2D1) or 20% PEG 4000, 100 mM sodium acetate, and 200 mM mag-
nesium acetate (del 2D1). Crystals were cryoprotected by the addition of
20%glyceroltothemotherliquorandﬂashcooledbyplungingintoliquid
nitrogen.
DiffractiondatawerecollectedattheStanfordSynchrotronRadiation
Lightsource (SSRL) beam line 9-2 (wt 2D1) and the Advanced Photon
Source (APS) NIH Medicine and Cancer Institutes Collaborative Access
Team (GM/CA-CAT) beam line 23ID-D (del 2D1) at the Argonne Na-
tionalLaboratory.Diffractiondatawereintegrated,scaled,andmergedin
HKL2000 (HKL Research). The structures were solved by molecular re-
placement using Phaser (23). The 1918 virus-bound 2D1 coordinates
(PDB code 3LZF) were used as a search model for wt 2D1 Fab, which was
in turn used to phase the del 2D1 data set. In each case, CDRs H1 and H3
were pruned before molecular replacement to minimize model bias. The
wt2D1anddel2D1structurescontaintwocopiesandonecopyoftheFab
intheasymmetricunit,respectively.Thewt2D1anddel2D1coordinates
were reﬁned in Phenix (24), including simulated annealing and
translation-libration-screw(TLS)withonegroupforeachIgdomain.The
models were adjusted, the CDRs were rebuilt, and waters were added in
the late stages of reﬁnement using Coot (25). The models were validated
using the JCSG Quality Control Server (version 2.7, publicly available at
http://smb.slac.stanford.edu/jcsg/QC/), which includes Molprobity (26).
Kabat numbering of the Fabs was assigned by the AbNum web server
(http://www.bioinf.org.uk/abs/abnum) (27), with modiﬁcation for 2D1
to accommodate the insertion, as discussed by Xu et al. (12). Final data
collection and reﬁnement statistics can be found in Table S1 in the sup-
plemental material.
Sequence accession numbers. Coordinates and structure factors for
wt 2D1 and del 2D1 have been deposited in the Protein Data Bank (PDB
codes 3QHZ and 3QHF, respectively).
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